ANIP - ANI Pharmaceuticals Inc


Weak GrowthEarnings/Profit is Negative


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 42.84%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -8.07%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 2.14
Debt Ratio is 0.6
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.43
Cash Flow is WEAK
Cash from Operations Growth is -72.38%
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
ANI Pharmaceuticals Inc (ANIP) -
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Patrick Walsh
Employees - 369

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.